Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 29. During the call, company executives will provide an overview of Merck’s performance for the quarter.
AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from MK-7240-012, a Phase 2b multicenter, randomized, double-blind, placebo-controlled trial evaluating tulisokibart, an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderate to severe hidradenitis suppurativa (HS). These data will be presented in a Late-Breaking News session at the European Academy of Dermatology and Venereology (EADV) 2026 Congress (Abstract ID: LB-26).
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...
Looking back on branded pharmaceuticals stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Merck (NYSE:MRK) and its peers. L...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. (“SciBrunch”), today announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the U.S. Food and Drug Administration (FDA) has approved the dual oral regimen of WELIREG® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
